Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives.

ABSTRACT: Hepatocellular carcinoma often develops in the context of chronic liver disease. It is the sixth most frequently diagnosed cancer and the third most common cause of cancer-related mortality worldwide. Although the mainstay of therapy is surgical resection, most patients are not eligible because of liver dysfunction or tumor extent. Sorafenib was the first tyrosine kinase inhibitor that improved the overall survival of patients who failed to respond to local therapies or had advanced disease, and for many years, it was the only treatment approved for the first-line setting. However, in recent years, trials have demonstrated an improvement in survival with treatments based on immunotherapy and new targeting agents, thereby extending the treatment options. A phase III trial showed that a comb

SUBMITTER: Girardi DM 

PROVIDER: S-EPMC10046570 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature